help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by RICE, K. L.
Right arrow Articles by NIEWOEHNER, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by RICE, K. L.
Right arrow Articles by NIEWOEHNER, D. E.

Am. J. Respir. Crit. Care Med., Volume 162, Number 1, July 2000, 174-178

Withdrawal of Chronic Systemic Corticosteroids in Patients with COPD
A Randomized Trial

KATHRYN L. RICE, JEFFREY B. RUBINS, FRAN LEBAHN, CONNIE M. PARENTI, PETER G. DUANE, MICHAEL KUSKOWSKI, ANNE M. JOSEPH, and DENNIS E. NIEWOEHNER

Department of Medicine and Geriatric Research Center, Minneapolis Veterans Affairs Medical Center and University of Minnesota, Minneapolis, Minnesota

The benefits of chronic systemic corticosteroids for patients with chronic obstructive pulmonary disease (COPD) are not well established. To determine whether chronic corticosteroid treatment can be safely withdrawn in "steroid-dependent" COPD patients, we performed a double-blind, placebo-controlled study of 38 patients with steroid-dependent COPD. Patients were randomly assigned to receive their usual maintenance prednisone dose for 6 mo (continuous group) or to be withdrawn from prednisone at a rate of 5 mg per week (demand group). The number of COPD exacerbations per patient (primary outcome) was 2.5 ± 2.7 (mean ± SD) in the continuous group and 2.7 ± 2.5 in the demand group (p = 0.60, 95% confidence interval for the difference: -1.1 to 1.7). Spirometric results, dyspnea, and health-related quality of life did not differ significantly in the two groups. The average daily corticosteroid dose was 10.7 ± 5.2 mg in the continuous group and 6.3 ± 6.4 mg in the demand group (p = 0.003). Weight decreased in the demand group by 4.8 ± 2.0 kg, compared with an increase in the continuous group of 0.5 ± 3.5 kg (p = 0.007). Discontinuation of chronic systemic corticosteroid treatment in steroid-dependent COPD patients did not cause a significant increase in COPD exacerbations, but did reduce total systemic corticosteroid use and body weight. Larger studies may be warranted to establish the relative risks and benefits of chronic corticosteroid treatment of patients with COPD.




This article has been cited by other articles:


Home page
 Proc Am Thorac SocHome page
J. A. Falk, O. A. Minai, and Z. Mosenifar
Inhaled and Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, May 1, 2008; 5(4): 506 - 512.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. E. Niewoehner, Y. Lokhnygina, K. Rice, W. G. Kuschner, A. Sharafkhaneh, G. A. Sarosi, P. Krumpe, K. Pieper, and S. Kesten
Risk Indexes for Exacerbations and Hospitalizations Due to COPD
Chest, January 1, 2007; 131(1): 20 - 28.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
J R Hurst and J A Wedzicha
Chronic obstructive pulmonary disease: the clinical management of an acute exacerbation
Postgrad. Med. J., September 1, 2004; 80(947): 497 - 505.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
K. H. Groenewegen, A. M.W.J. Schols, and E. F.M. Wouters
Mortality and Mortality-Related Factors After Hospitalization for Acute Exacerbation of COPD
Chest, August 1, 2003; 124(2): 459 - 467.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. S. Irwin and J. M. Madison
Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease
N. Engl. J. Med., June 26, 2003; 348(26): 2679 - 2681.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
J. M. Singh, V. A. Palda, M. B. Stanbrook, and K. R. Chapman
Corticosteroid Therapy for Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Systematic Review
Arch Intern Med, December 9, 2002; 162(22): 2527 - 2536.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. V. Culpitt, C. de Matos, R. E. Russell, L. E. Donnelly, D. F. Rogers, and P. J. Barnes
Effect of Theophylline on Induced Sputum Inflammatory Indices and Neutrophil Chemotaxis in Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., May 15, 2002; 165(10): 1371 - 1376.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2000
Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1789 - 1804.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. A. PAUWELS, A. S. BUIST, P. M. A. CALVERLEY, C. R. JENKINS, and S. S. HURD
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease . NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary
Am. J. Respir. Crit. Care Med., April 1, 2001; 163(5): 1256 - 1276.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2000 American Thoracic Society 		  ATS State of the Art 2009